Skip to main content

Table 3 Crude and adjusted Hazards Ratios for Carcinosarcoma progression-free survival (PFS) estimated by univariate analysis and multivariate analysis

From: The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma

Clinicopathological features

Univariate analysis

Multivariate analysis

HR

95%CI

p-value

HR

95%CI

p-value

Age (<  60 vs. ≥ 60)

1.03

0.99–1.07

0.171

1.03

0.99–1.07

0.111

Stage (I/II vs III/IV)

0.37

0.16–0.84

0.017

–

–

–

Residual disease (R1/2 vs R0)

4.19

2.13–8.25

0.001

3.09

1.34–7.08

0.008

Adjuvant radiotherapy (Yes vs No)

0.57

0.30–1.08

0.087

0.66

0.34–1.26

0.213

LVI (present vs absent)

1.06

0.50–2.25

0.872

1.05

0.49–2.22

0.906

Histological subtype (Homologous vs Heterologous)

0.83

0.39–1.78

0.631

0.94

0.44–2.02

0.885

CD3_E (high vs low)

0.58

0.31–1.08

0.086

0.67

0.26–1.27

0.229

CD3_S (high vs low)

0.48

0.15–1.57

0.225

0.62

0.19–2.07

0.439

CD4_E (high vs low)

0.39

0.21–0.74

0.004

0.43

0.23–0.82

0.010

CD4_S (high vs low)

0.62

0.80–3.21

0.184

0.60

0.30–1.20

0.153

CD8_E (high vs low)

0.67

0.35–1.29

0.232

0.61

0.31–1.19

0.151

CD8_S (high vs low)

0.86

0.42–1.75

0.669

0.71

0.34–1.48

0.364

FOXP3_E (high vs low)

0.55

0.26–1.17

0.120

0.54

0.26–1.16

0.115

FOXP3_S (high vs low)

0.41

0.14–1.15

0.090

0.42

0.15–1.19

0.103

PD-1_E (high vs low)

0.47

0.25–0.90

0.022

0.54

0.28–1.04

0.065

PD-1_S (high vs low)

0.66

0.31–1.41

0.286

0.73

0.34–1.56

0.420

PD-L1_E (high vs low)

0.47

0.25–0.88

0.019

0.45

0.24–0.84

0.013

PD-L1_S (high vs low)

0.28

0.12–0.67

0.004

0.30

0.12–0.74

0.008

PD-L2_E (high vs low)

0.48

0.22–1.06

0.070

0.62

0.28–1.38

0.241

PD-L2_S (high vs low)

0.46

0.16–1.31

0.147

0.43

0.15–1.22

0.114

CD4/FOXP3_E ratio (high vs low)

0.57

0.31–1.04

0.067

0.63

0.34–1.16

0.141

CD4/FOXP3_S ratio (high vs low)

1.43

0.76–2.67

0.267

1.65

0.87–3.11

0.120

CD8/FOXP3_E ratio (high vs low)

0.74

0.39–1.41

0.363

0.84

0.44–1.60

0.605

CD8/FOXP3_S ratio (high vs low)

2.27

1.21–4.26

0.010

2.05

1.08–3.85

0.026

CD8/CD4_E ratio (high vs low)

0.61

0.24–1.56

0.299

0.51

0.20–1.33

0.171

CD8/CD4_S ratio (high vs low)

1.69

0.78–3.67

0.186

1.87

0.86–4.10

0.113

  1. All variables were adjusted for staging in multivariate analysis. Significant P-values are emboldened
  2. LVI Lymphovascular Invasion, E Epithelial Component, S Sarcomatous Component, ER Estrogen Receptor, PR Progesterone Receptor, CD3 Cluster of Differentiation 3, CD4 Cluster of Differentiation 4, CD8 Cluster of Differentiation 8, FOXP3 Forkhead Box P3, PD-1 Programmed Cell Death Protein 1, PD-L1 Programmed Death-Ligand 1, PD-L2 Programmed Death-Ligand 2
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us